I decided to stay at Fox Chase Cancer Center after completing my fellowship here because I believe in the mission of this center. I believe that Fox Chase provides my patients with an environment that is not only patient friendly but also a place that great care can be delivered. I can offer many of the top clinical trials to my patients if needed and help advance the field of lung cancer therapy. With the dedicated nurses, social workers and support staff at Fox Chase I have the right team in place to help me care for my patients.
I also believe that we treat more than just a disease. I consider the patient as a whole, an individual with a disease and not just the disease. I believe in engaging patients and their families in their care to the extent that my patients allow it. I believe in a team approach to the care of patients with lung cancer and along with my colleagues in the thoracic division we can deliver the best level of care that is possible.
My laboratory concentrates on the development of new cancer treatments with an emphasis on the use of immunotherapy and monoclonal antibodies. We are capable of making new monoclonal antibodies against various cancer related targets and have recently received a patent for one such antibody. In collaboration with a number of other scientists at Fox Chase and as a result of laboratory based studies conducted here, I have developed clinical trials that are ongoing for treatment of patients with lung cancer.
My collaborations with scientists outside of Fox Chase also is an important part of what I do with the aim of bringing newer and more effective immune based treatments to the clinic. My laboratory also examines patients’ tumors to try to learn why some patients respond to specific treatment while others don’t. Discovery of new or better ways of treating cancer is an important part of my activities here.
In addition to laboratory based investigations, I am active in clinical trials. My goal is to offer my patients some of the best options that are available. I believe that clinical trials, when offered appropriately, can not only help us develop the next best treatment options but also allow my patients access to potentially new and promising drugs.
In addition I am actively involved in lung cancer screening and research involving potential preventative measures with the hope of detecting lung cancer early and preventing recurrences of this disease.
Chief Fellow, Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, PA
Resident, Graduate Hospital, Philadelphia, PA
DO, Philadelphia College of Osteopathic Medicine, 1996
Sometimes I think that my timing was just incredible. If I had been diagnosed with cancer a few years earlier, my prognosis would have looked much different than it does today—especially if I had not gone to Fox Chase!
After being diagnosed with peritoneal mesothelioma, a rare form of cancer, Preston Moyer underwent life-saving treatment, including chemotherapy and surgery at Fox Chase Cancer Center. With the help of Dr. Sanjay Reddy and Dr. Hossein Borghaei, Preston is now cancer free.
Monoclonal Antibody, Targeted Therapy, Immunotherapy, Cancer Vaccine
Borghaei H., Redman M.W., Kelly K., Waqar S.N., Robert F., Kiefer G.J., Stella P.J., Minichiello K., Gandara D.R., Herbst R.S., Papadimitrakopoulou V.A., Swog s1400a (nct02154490): A phase ii study of durvalumab for patients with previously treated stage iv or recurrent squamous cell lung cancer (lung-map sub-study). Clin Lung Cancer. 22(3): 178-186, 2021.PMC8686189. https://www.ncbi.nlm.nih.gov/pubmed/33358401.
Borghaei H., Gettinger S., Vokes E.E., Chow L.Q.M., Burgio M.A., de Castro Carpeno J., Pluzanski A., Arrieta O., Frontera O.A., Chiari R., Butts C., Wójcik-Tomaszewska J., Coudert B., Garassino M.C., Ready N., Felip E., García M.A., Waterhouse D., Domine M., Barlesi F., Antonia S., Wohlleber M., Gerber D.E., Czyzewicz G., Spigel D.R., Crino L., Eberhardt W.E.E., Li A., Marimuthu S.,Brahmer J., Five-year outcomes from the randomized, phase iii trials checkmate 017 and 057: Nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 39(7): 723-733 2021.PMC8078445. https://www.ncbi.nlm.nih.gov/pubmed/33449799.
Judd J., Abdel Karim N., Khan H., Naqash A.R., Baca Y., Xiu J., VanderWalde A.M., Mamdani H., Raez L.E., Nagasaka M., Pai S.G., Socinski M.A., Nieva J.J., Kim C., Wozniak A.J., Ikpeazu C., de Lima Lopes G., Jr., Spira A.I., Korn W.M., Kim E.S., Liu S.V., Borghaei H., Characterization of kras mutation subtypes in non-small cell lung cancer. Mol Cancer Ther. 20(12): 2577-2584, 2021. https://www.ncbi.nlm.nih.gov/pubmed/34518295.
Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Chih-Hsin Yang J, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller S, Gandhi L. 24-Month Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab As First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018. PubMed
Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, Hawkins R, Dueland S, Lassen U, Cohen RB. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:4116-23. PubMed
Borghaei H, Alpaugh RK, Bernardo P, Palazzo IE, Dutcher JP, Venkatraj U, Wood WC, Goldstein L, Weiner LM. Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): A Trial Coordinated by the Eastern Cooperative Oncology Group. J Immunother. 2007;30:455-467. PubMed
Hossein Borghaei, Barry Jones, Chris Kiritsy, Jack H Lai and William Bachovchin. Overcoming the KRAS resistance mechanism by augmenting antibody-dependent cellular cytotoxicity. Colorectal Cancer, 2012, 1(4), 273-275.
Mateo J, Berlin J, de Bono JS, Cohen RB, Keedy V, Mugundu G, Zhang L, Abbattista A, Davis C, Gallo Stampino C, Borghaei H. A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Sep 12. PubMed
Jalal SI, Hanna N, Zon R, Masters GA, Borghaei H, Koneru K, Badve S, Prasad N, Somaiah N, Wu J, Yu Z, Einhorn L. Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130.Am J. Clin Oncol. 2014, Dec 10. PubMed
Moran T, Felip E, Keedy V, Borghaei H, Shepherd FA, Insa A, Brown H, Fitzgerald T, Sathyanarayanan S, Reilly JF, Mauro D, Hsu K, Yan L, Johnson DH. Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial. Exp Hematol Oncol. 2014 Nov 7;3(1):26. doi: 10.1186/2162-3619-3-26. PubMed...Expand
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39. PubMed
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw. 2015 May;13(5):515-24. PubMedCollapse
Our Patient Satisfaction Rating is an average of all responses to care provider related questions from our
nationally-recognized Press Ganey Patient Satisfaction Survey.
5.0 / 5.0
Gives easy to understand instruction
Explains in a way you understand
Listens carefully to you
Shows respect for what you say
Spends enough time with you
11 patient comments
No Star Ratings Available
March 28, 2022
Caring and thoughtful.
March 16, 2022
I am very Happy with my Doctor and all the staff at Fox Chase. They are the best
March 11, 2022
All involved 11+.
November 13, 2021
Very good and helpful second opinion
October 1, 2021
I have been very happy & satisfied with the excellent care from Dr. Borghaei.
July 28, 2021
I can't speak highly enough about Dr Borghaei. He is an absolute gem of doctor and I couldn't imagine trusting my lung health with anyone else. Feel blessed to be his patient.
No Star Ratings Available
June 28, 2021
Dr. Borghaei is a skilled, caring physician.
June 22, 2021
Dr. Borghaei and the staff who take care of me are wonderful. I feel I am in the best hands at Fox Chase.
May 28, 2021
While he stated would ave his second opinion by the following Mon. he was on phone with my oncologist before we even got home and a course of action was decided which was discussed the following morning with me!
April 15, 2021
Dr. Borghaei and his staff are the greatest.
January 8, 2021
Dr. Borghaei & his team are the best. He is so professional & meets the physical & emotional needs of the patient.